Newcourt (NASDAQ:NCAC) has closed its combination with psychedelic medicine company Psyence (CSE:PSYG) and will begin trading on The Nasdaq under the new ticker symbol ticker symbol “PBM” on January 26.
Shareholders previously approved the combination during a special meeting held on January 18.
In connection with last week’s vote, shareholders opted to redeem 929,727 shares at a redemption price of approximately $11.51 per share, removing about $10.7 million from Newcourt’s trust and leaving it with 183,294 public shares outstanding and about $2.1 million in trust.
In connection with the combination, Psyence Biomed entered into a securities purchase agreement under which it will raise up to $10 million in funding through the issuance of up to four senior secured convertible notes with a US-based investment firm. The combined company intends to use the note financing to further its clinical trials conducted in Australia.
Psyence Biomed has partnered with the Australian-based research organization iNGENu to conduct its clinical trial in palliative care. Upon successful completion of the study, the combined company plans to conduct a multinational Phase III study.
The SPAC announced its deal with Psyence in January 2023. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.
Psyence Biomedical plans to use the funds from the deal to expedite its clinical trials and expand its market presence.
ADVISORS
- Bayline Capital Partners Inc. is acting as capital markets advisor to Psyence.
- WeirFoulds LLP is acting as Canadian legal advisor to Psyence.
- Morgan, Lewis & Bockius LLP is acting as U.S. legal advisor to Psyence.
- McDermott Will & Emery LLP is acting as U.S. legal advisor to Newcourt.
In March 2025, SPAC activity remained largely in line with February, though notable shifts emerged across extensions, announced transactions, and completions. Extension activity remained steady, with a slight increase in the number of SPACs seeking additional time. However, later-stage extensions became more common, reflecting a maturing SPAC landscape. Announced transaction volume continued to be weak,...
Best SPAC I (NASDAQ:BSAAU) has filed for a $55 million SPAC with a search focus targeting consumer goods companies from its base in Hong Kong. Maxim is taking just 1.0% fees up front and will not take a deferred fee. This upfront fee will also apply only to proceeds in the offering from investors brought...
At the SPAC of Dawn Two new SPACs priced their IPOs yesterday, showing that SPACs at least are not entirely spooked by the markets continued downturn. Futures continue to be beet red heading into the second day of the week, particularly for the SPAC-favorite exchange Nasdaq. SPACs have the potential to shine in this environment,...
An In-Depth Look at SPAC Activity Through the First Quarter 2025 Below is a summary of the Q1-2025 SPAC market. If you’d like a pdf copy, you can access the link HERE. While SPAC IPO issuance has continued to climb modestly in Q1, it’s doing so at a more sustainable and disciplined pace compared to...
Siddhi Acquisition Corp. (NASDAQ:SDHIU) announced the pricing of its upsized $240 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “SDHIU”, Tuesday, April 1, 2025. The new SPAC plans to mount a broad search for a target company leveraging its internal network of relationships. Siddhi is to be...